€36 Mio funding – INNODIA launched under IMI2

ts_gj_kdj

Torild Skrivarhaug, Geir Joner and Knut Dahl-Jørgensen. Photo: OUS/UiO.

Torild Skrivarhaug, Geir Joner and Knut Dahl-Jørgensen represent Oslo Diabetes Research Centre in the international consortium INNODIA which recently was granted €36 Mio funding. The IMI2-supported public private partnership consists of research institutions and clinics, pharmaceutical companies, enterprises and patient organizations worldwide. Altogether 33 partner institutions will contribute with their expertise to significantly improve the understanding of type 1 diabetes and work towards better therapies for preventing and curing this disease.

It is a great recognition for Oslo Diabetes Research Center to be invited into such a consortium and it is important for us to participate in this network of Europe’s best researchers in this field, especially from the basal medical research laboratories. INNODIA will also have the expertise and resources to handle large amounts of data, e.g. related to omics and genetics. Our center can get resources to participate in large multi-center clinical trials through INNODIA.

INNODIA-Kick-off-Meeting-Frankfurt-Jan-17th-19th_web

On January 19th 2016 the INNODIA project was kicked-off in Frankfut/Main by the project partners.

Researchers from Oslo Diabetes Research Centre will contribute with data from the biobank affiliated Children Diabetes Registry.In addition, they will contribute with data and the biobank from the project “Arteriosclerosis and childhood diabetes”. The research group is currently working to determine if virus or other environmental factors may be a trigger for type 1 diabetes. As members of INNODIA consortium we will get access to good basic medical laboratories to further develop this research.